In this study, we designed a novel fusion peptide immunogen including human MSLN, PD-L1 immune checkpoint molecule, GM-CSF sequence and T helper epitope sequence assembly as therapeutic tumor vaccine (MSLN-PDL1-GMCSF). Here, MSLN is linked to neoplasm.